C4 Therapeutics Doses First Patient in Phase 2 MOMENTUM Trial of Cemsidomide in Multiple Myeloma

Reuters02-23

C4 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Doses First Patient in Phase 2 MOMENTUM Trial of Cemsidomide in Multiple Myeloma

C4 Therapeutics said it has dosed the first patient in its Phase 2 MOMENTUM trial evaluating cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone for relapsed/refractory multiple myeloma in the fourth line or later setting. The open-label, single-arm, multicenter study plans to enroll about 100 patients at a 100 µg dose level, with cemsidomide given 14 days on/14 days off and dexamethasone dosed weekly; the primary endpoint is overall response rate assessed by an independent review committee under International Myeloma Working Group criteria. The company said it expects to complete enrollment in Q1 2027, initiate a Phase 1b combination trial with elranatamab in Q2 2026, and report further analysis from the completed Phase 1 cemsidomide plus dexamethasone trial in mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658839-en) on February 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613781885?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-23 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613781885","market":"fut","top_or_hot":-1,"title":"C4 Therapeutics Doses First Patient in Phase 2 MOMENTUM Trial of Cemsidomide in Multiple Myeloma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      C4 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Doses First Patient in Phase 2 MOMENTUM Trial of Cemsidomide in Multiple Myeloma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        C4 Therapeutics said it has dosed the first patient in its Phase 2 MOMENTUM trial evaluating cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone for relapsed/refractory multiple myeloma in the fourth line or later setting. The open-label, single-arm, multicenter study plans to enroll about 100 patients at a 100 µg dose level, with cemsidomide given 14 days on/14 days off and dexamethasone dosed weekly; the primary endpoint is overall response rate assessed by an independent review committee under International Myeloma Working Group criteria. The company said it expects to complete enrollment in Q1 2027, initiate a Phase 1b combination trial with elranatamab in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, and report further analysis from the completed Phase 1 cemsidomide plus dexamethasone trial in mid-2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658839-en) on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>C4 Therapeutics Doses First Patient in Phase 2 MOMENTUM Trial of Cemsidomide in Multiple Myeloma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nC4 Therapeutics Doses First Patient in Phase 2 MOMENTUM Trial of Cemsidomide in Multiple Myeloma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-23 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      C4 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Doses First Patient in Phase 2 MOMENTUM Trial of Cemsidomide in Multiple Myeloma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        C4 Therapeutics said it has dosed the first patient in its Phase 2 MOMENTUM trial evaluating cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone for relapsed/refractory multiple myeloma in the fourth line or later setting. The open-label, single-arm, multicenter study plans to enroll about 100 patients at a 100 µg dose level, with cemsidomide given 14 days on/14 days off and dexamethasone dosed weekly; the primary endpoint is overall response rate assessed by an independent review committee under International Myeloma Working Group criteria. The company said it expects to complete enrollment in Q1 2027, initiate a Phase 1b combination trial with elranatamab in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, and report further analysis from the completed Phase 1 cemsidomide plus dexamethasone trial in mid-2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658839-en) on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL9nx2nC:1","article_id":"2613781885","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613781885","pubTimestamp":1771848030,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","CCCC":"C4 Therapeutics, Inc.","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","NDAQ":"纳斯达克OMX交易所","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"C4 Therapeutics在Cemsidomide治疗多发性骨髓瘤的2期MOMENTUM试验中为首例患者进行给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CCCC":0.9,"NDAQ":0.9},"content_text":"C4 Therapeutics Doses First Patient in Phase 2 MOMENTUM Trial of Cemsidomide in Multiple Myeloma\n    \n\n        C4 Therapeutics said it has dosed the first patient in its Phase 2 MOMENTUM trial evaluating cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone for relapsed/refractory multiple myeloma in the fourth line or later setting. The open-label, single-arm, multicenter study plans to enroll about 100 patients at a 100 µg dose level, with cemsidomide given 14 days on/14 days off and dexamethasone dosed weekly; the primary endpoint is overall response rate assessed by an independent review committee under International Myeloma Working Group criteria. The company said it expects to complete enrollment in Q1 2027, initiate a Phase 1b combination trial with elranatamab in Q2 2026, and report further analysis from the completed Phase 1 cemsidomide plus dexamethasone trial in mid-2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658839-en) on February 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613781885","isCrawlerRequest":true}